Literature DB >> 3088987

Sclerosing encapsulating peritonitis: report of a case with small bowel obstruction managed by long-term home parenteral hyperalimentation, and a review of the literature.

R Pusateri, R Ross, R Marshall, J H Meredith, R W Hamilton.   

Abstract

Sclerosing peritonitis has recently emerged as a complication of peritoneal dialysis associated with a high morbidity and mortality. These patients experience the characteristic syndrome of nausea, vomiting, abdominal pain, partial small bowel obstruction, and impaired ultrafiltration. A pathologic finding is the replacement of mesothelial cells with a thick layer of nondistensible fibroconnective tissue. We report here a 58-year-old white woman who developed peritoneal sclerosis after 4 years of peritoneal dialysis, including 3 years of continuous ambulatory peritoneal dialysis. Risk factors included peritoneal exposure to low concentrations of formaldehyde and a 1-week exposure to long-dwell acetate dialysate. Laparotomy for partial small bowel obstruction with resection of the involved segment was complicated by enterocutaneous fistulae, which improved only on cessation of oral intake and treatment with home parenteral nutrition. We have reviewed the literature to find 20 cases of sclerosing peritonitis in patients on peritoneal dialysis. A 78% mortality rate is reported in cases that had surgical intervention. We conclude that the use of long-term parenteral nutrition with cessation of oral intake may be necessary in the management of sclerosing encapsulating peritonitis.

Entities:  

Mesh:

Year:  1986        PMID: 3088987     DOI: 10.1016/s0272-6386(86)80155-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  1 in total

1.  Clinical risk factors and outcomes of massive ascites accumulation after discontinuation of peritoneal dialysis.

Authors:  Ming-Shan Chang; Nai-Ching Chen; Chih-Yang Hsu; Chien-Wei Huang; Po-Tsang Lee; Kang-Ju Chou; Hua-Chang Fang; Chien-Liang Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.